Zehender, Ariella
Huang, Jingang
Györfi, Andrea-Hermina
Matei, Alexandru-Emil http://orcid.org/0000-0003-1248-3145
Trinh-Minh, Thuong
Xu, Xiaohan
Li, Yi-Nan
Chen, Chih-Wei
Lin, Jianping
Dees, Clara
Beyer, Christian
Gelse, Kolja
Zhang, Zhong-Yin
Bergmann, Christina
Ramming, Andreas
Birchmeier, Walter
Distler, Oliver
Schett, Georg
Distler, Jörg H. W.
Article History
Received: 30 October 2017
Accepted: 25 July 2018
First Online: 14 August 2018
Competing interests
: None of the authors has any direct financial interest related to SHP2. O.D. has consultancy relationships and/or has received research funding for the treatment of SSc from Actelion, Pfizer, Ergonex, BMS, Sanofi-Aventis, United BioSource Corporation, Roche/Genentech, Medac, Biovitrium, Boehringer Ingelheim, Novartis, 4D Science, Active Biotech, Bayer, Sinoxa, Serodapharm, EpiPharm, GSK, Pharmacyclics and Biogen. J.H.W.D. has consultancy relationships for fibrotic diseases with Actelion, Active Biotech, Anamar, Bayer Pharma, Boehringer Ingelheim, Celgene, Galapagos, Inventiva, JB Therapeutics, Medac, Pfizer, RuiYi and UCB in the area of potential treatments of SSc. J.H.W.D. has received research funding for projects on fibrosis from Anamar, Active Biotech, Array Biopharma, BMS, Bayer Pharma, Boehringer Ingelheim, Celgene, GSK, Novartis, Sanofi-Aventis, UCB in the area of potential treatments of SSc. J.H.W.D. is stock owner of 4D Science GmbH. The remaining authors declare no competing interests.